Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)
January 25, 2021 10:57 AM EST
Coronavirus

Covid-19 roundup: Mod­er­na dou­bles down on Covid-19 with new boost­er tri­als; Aus­tralia plans do­mes­tic pro­duc­tion of As­traZeneca vac­cine amid dis­tri­b­u­tion lag

Nicole DeFeudis

Editor

As Mer­ck bows out of the glob­al race to de­vel­op vac­cines for Covid-19, Mod­er­na is dou­bling down to make sure they can quell new vari­ants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times